Capacity surge tempered by margin pressure; recovery pathway clear

₹178.7 Cr is 23.8% of ₹750 Cr; split requires ~34% in H1, so Q1 ahead

Q4 FY26: 38.1%; Q1 FY27: 41.8% = 370 bps expansion

14.9% vs 14.4% = 50 bps, achieved on 9.7% revenue decline

154.66M / 105M = 1.473 = 47.3% uplift confirmed in call

₹8 Cr vs ₹13.2 Cr Q4 = 39.4% decline; call attributes to revenue base + 'normalized tax'; conveniently excludes Noumed one-off freight costs

No quantified guidance for FY28; positioned as forward-looking inflection

Was: Unit-1/2 upgradation. Now: 60% Saicriti (47% more capacity, faster timeline). Regulatory driver (HILTP policy Feb 2026) justified shift. No guidance impact.

₹15 Cr (vs ₹18 Cr originally planned Greenfield R&D center). Acquired operating platform: 150 SKUs, 86 molecules, 65 staff, 28+ scientists. Removes 7-8 month build cycle.

Locked AUD 202M (~₹1,300 Cr) over 7.5 years (avg AUD 27M/year), with 3-year extension option to 2036. Built-in 12 new products/year growth via Sai R&D. Ties customer in through 2036.

Q1 came in 210 bps below target. Management blames supply/airfreight (one-off), raw material recovery partial (expects full Q2+). Credibility hinges on Q2 recovery.

Above it. AUD 202M is existing portfolio baseline. 12 new products per year will expand scope and value per launch, but base order is on current supply mix.

Yes, there should be. Forecast-based order is sound at AUD 27M/year. Customer network grows 5-8% YoY via new pharmacy adds (~35 net annually).

Several multinational conversations in progress; cannot elaborate yet. Leveraging own IP dossiers and tech transfer.

Noumed team (Mark owns 25.4%) is autonomous. Prathyak retains 4 senior mgmt (28+ years exp each). Sai supports via manufacturing, R&D space, procurement. Not doing everything in-house.

Hyderabad HILTP policy (Feb 2026) forbade upgrades within outer ring road. Jeedimetla site only 3,100 sq yards (need 12,000-13,000). Greenfield would take 7-8 months for land alone. Saicriti facility pre-started on 15,000 sq yards with 52 Cr domestic business. 60% deal: 47% more capacity on same CAPEX, April 2027 completion (1 month delay), US FDA capable (50% upgradation from original EU-only plan).

Target Europe, ROW, SE Asia, Latin America, Middle East first. 150 molecules already in Prathyak pipeline ready to transfer; will avoid development cycle. US FDA option later post-completion.

Unit-1/2 do domestic market, not export-qualified. Survey shows major ROW/Europe market for critical-care injectables. Existing exports only oral + Cephalosporins. New facility adds lyophilised/GLP export capability to address market opportunity.

One-off. West Asia supply constraints forced airfreight + regulatory costs. Margin hit in Q1 due to delays. Resolved now.

Sticking to ₹750 Cr, 17% EBITDA for FY27. For FY28, not thought deeply yet; need to see 3 more quarters to commit numbers. Will discuss next quarter if warranted.

Yes. Q1 performed above 45:55 split (at 44%). EBITDA only 2% below 17% target due to one-off airfreight (resolved). Next quarters should show clearer trajectory to 750/17% crossing.

No. Established by Critigen Pharma + Questus Pharma independently. Sai awaiting shareholder approval for entry; no connection today.

Critigen Pharma (100% today) + Questus Pharma (subsidiary) hold 40%. Project ₹217 Cr: Sai ₹83.83 Cr (60%), them ~₹56 Cr (40%), balance project debt. They have ₹52-53 Cr domestic sales currently via CMO; post-completion will migrate to Saicriti facility → OPEX savings first year.

67 people, 28 senior researchers, top 5 have 25+ years experience. Expertise: lyophilised, liposomal, oncology injectables, critical-care Cephalosporins. Will start Sai/Noumed development immediately upon acquisition; removes build cycle.

Too premature. Board approved formation only. Under evaluation for market entry opportunities. Will update shareholders/market when opportunity seized and evaluation complete.

Singapore entity used for Noumed Australia (tax benefits SG-AUS). US is preliminary; haven't evaluated tax benefits yet. Will revert as strategy evolves.

Current debt ₹310 Cr (June 2026) vs ₹320 Cr (March 2026 — improved ₹10 Cr). Repaid ₹50 Cr loans post-IPO. Debt/Equity 0.6x well-placed. Saicriti will add debt per 60%-40% split; expected to maintain 0.6x Debt/Equity. De-leveraging from FY28 as assets contribute.

Q1 is 23.8% of target, ahead of 45:55 split needing 33.75%. H2 historically weighted 55%; management confident in trajectory.

Q1 delivered 14.9%, -210 bps miss. Raw material recovery expected full in Q2+. One-off airfreight absorbed Q1 (resolved). Confidence hinges on Q2 recovery.

Regulatory-driven (HILTP policy). Civil work underway. Completion April 2027 locked in funding.

Operating acquisition closes Sep 2026. No build cycle risk.

Physical completion Jan 2027, TGA March 2027, Phase 1 April 2027.

Saicriti (April 2027), Prathyak (Sep 2026), Australia Phase 1 (April 2027) converge within 6 months. Management depth at Noumed + Prathyak mitigates, but track record on concurrent integrations untested.

Analyst raised downward realization trend in injectables. Management attributed to domestic positioning (exports only oral + Cephalosporins). New facility addresses export gap but doesn't solve domestic pricing power.

Gross debt ₹310 Cr on ₹184 Cr cash (net ₹126 Cr). Debt/Equity 0.6x comfortable now but will rise with Saicriti additional debt. De-leveraging expected FY28 if new assets contribute earnings; if delayed, debt service could constrain growth.

Currently hold 9-10 months inventory due to 60-90 day shipping from India CMO network. West Asia disruptions (Q1) forced airfreight, hitting margin 200+ bps. Adelaide Phase 1 (April 2027) will shift to local manufacturing, reducing lead time to 5-6 months.

Board approved US subsidiary formation through Singapore holding company. Strategy at preliminary evaluation stage; management explicitly deferred disclosure ('too premature'). No quantified market opportunity or Go-to-Market plan shared.